{"title": "Scientific studies", "author": null, "url": "https://sputnikvaccine.com/about-vaccine/scientific-studies/", "hostname": "sputnikvaccine.com", "description": "Scientific studies | Official website vaccine against coronavirus Sputnik V.", "sitename": "Official website vaccine against COVID-19 Sputnik V.", "date": "2021-08-22", "cleaned_text": "Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals Country: Italy Key facts Read the article Sputnik V demonstrates strong protection against Omicron variant, more than 2 times higher virus neutralizing activity than Pfizer vaccine against Omicron Neutralization antibody titer Omicron Source: variant Sputnik V vaccinated individuals\u00bb The study demonstrates that Sputnik V neutralizes Omicron variant inducing robust antibody response associated with high levels of protection Each group of sera samples was divided into 7 parts level Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant Country: Russia Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-VE study Country: Hungary COVID-19 in the Republic of Belarus: pandemic features and the interim safety and efficacy assessment of the Gam-COVID-Vac vaccine Country: Belarus Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran Country: Iran Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine \"Sputnik Light\" for prevention of coronavirus infection in healthy adults Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country Country: Argentina Boosting of the SARS-CoV-2-specific immune response after vaccination with single-dose Sputnik Light vaccine Safety and Effectiveness of COVID-19 SPUTNIK V Vaccine in Dialysis Patients Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow SARS-CoV-2 vaccines breakthrough infection hospitalizations after one dose in Libya: cohort study Country: Libya SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report Country: Serbia Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina Temporal Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape after Sputnik V Vaccination Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac) Country: Sri Lanka Neutralizing Activity of Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance Country: San Marino Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina Estimating SARS-CoV-2 Spike Antibody Levels Among Sputnik V First Dose Vaccinated People in Pakistan: Formulation of Anti-COVID-19 National Mass Vaccination Strategy Country: Pakistan Evaluation of the neutralizing antibodies response to Sputnik V vaccine in a cohort in the city of C\u00f3rdoba and evaluation of the neutralizing properties of the natural and vaccine antibodies against the Manaus variant Sputnik V elicits a high immune response even with a single dose Sputnik V COVID-19 vaccine candidate appears safe and effective Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Message "}